Randomized trials of chemotherapy versus chemoimmunotherapy
| Study and treatment . | No. of patients . | Median FU, mo . | OR, % . | CR, % . | Median TTF, mo* . | OS, % . | P . |
|---|---|---|---|---|---|---|---|
| M3902162 | 53 | ||||||
| CVP | 159 | 57 | 10 | 15 | 77 | .029 | |
| R-CVP | 162 | 81 | 41 | 34 | 83 | ||
| GLSG63 | 18 | ||||||
| CHOP | 205 | 90 | 17 | 29 | 90 | .016 | |
| R-CHOP | 223 | 96 | 20 | NR | 95 | ||
| M3902364 | 47 | ||||||
| MCP | 96 | 75 | 25 | 26 | 74 | .010 | |
| R-MCP | 105 | 92 | 50 | NR | 87 | ||
| FL200065 | 42 | ||||||
| CHVP-IFN | 183 | 73 | 63 | 46 | 84 | .010 | |
| R-CHVP-IFN | 175 | 84 | 79 | 67 | 91 |
| Study and treatment . | No. of patients . | Median FU, mo . | OR, % . | CR, % . | Median TTF, mo* . | OS, % . | P . |
|---|---|---|---|---|---|---|---|
| M3902162 | 53 | ||||||
| CVP | 159 | 57 | 10 | 15 | 77 | .029 | |
| R-CVP | 162 | 81 | 41 | 34 | 83 | ||
| GLSG63 | 18 | ||||||
| CHOP | 205 | 90 | 17 | 29 | 90 | .016 | |
| R-CHOP | 223 | 96 | 20 | NR | 95 | ||
| M3902364 | 47 | ||||||
| MCP | 96 | 75 | 25 | 26 | 74 | .010 | |
| R-MCP | 105 | 92 | 50 | NR | 87 | ||
| FL200065 | 42 | ||||||
| CHVP-IFN | 183 | 73 | 63 | 46 | 84 | .010 | |
| R-CHVP-IFN | 175 | 84 | 79 | 67 | 91 |
FU indicates follow-up; OR, odds ratio, CR, complete remission; TTF, time to treatment failure; OS, overall survival; MCP, mitoxantrone, chlorambucil and prednisolone; and CHVP, cyclophosphamide, doxorubicin, teniposide, and prednisone.
*P values for TTF in all studies were less than .001.